Evaluation of radiation effects against C6 glioma in combination with vaccinia virus-p53 gene therapy.
The primary objective of this study was to evaluate the antitumor effects of recombinant vaccinia virus-p53 (rVV-p53) in combination with radiation therapy against the C6 rat glioma, a p53 deficient tumor that is relatively radioresistant. VV-LIVP, the parental virus (Lister strain), was used as a control. Localized treatment of subcutaneous C6 tumors in athymic mice with either rVV-p53 or VV-LIVP together with tumor irradiation resulted in low tumor incidence and significantly slower tumor progression compared to the agents given as single modalities. Assays of blood and spleen indicated that immune system activation may account, at least partly, for the enhance tumor inhibition seen with combined treatment. No overt signs of treatment-related toxicity were noted.
Gridley
D S
DS
Cancer Research Institute, Room A-1010, Loma Linda University School of Medicine, Loma Linda, CA 92354, USA.
Andres
M L
ML
Li
J
J
Timiryasova
T
T
Chen
B
B
Fodor
I
I
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D003131:Combined Modality Therapy; D015316:Genetic Therapy; D005910:Glioma / Q000453:epidemiology / Q000532:radiotherapy* / Q000628:therapy*; D015994:Incidence; D007371:Interferon-gamma / Q000097:blood; D007958:Leukocyte Count; D008070:Lipopolysaccharides / Q000494:pharmacology; D008213:Lymphocyte Activation; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D013154:Spleen / Q000187:drug effects / Q000473:pathology; D016159:Tumor Suppressor Protein p53 / Q000009:adverse effects / Q000235:genetics* / Q000627:therapeutic use; D014616:Vaccinia virus / Q000235:genetics
D008070:Lipopolysaccharides; D016159:Tumor Suppressor Protein p53; D007371:Interferon-gamma